Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 88Cr 76Cr 71Cr 65Cr 123.34Cr 8.39TCr 125.25Cr 838.55Cr 329.11Cr 4.18TCr 330.2Cr 322.94Cr 14TCr P/E 2026 *
14.9x
P/E 2027 * 11.3x
Enterprise Value 120.45Cr 104.71Cr 97Cr 89Cr 168.98Cr 11TCr 171.59Cr 1.15TCr 450.87Cr 5.72TCr 452.37Cr 442.43Cr 19TCr EV / Sales 2026 *
1.62x
EV / Sales 2027 * 1.39x
Free-Float
50.29%
Yield 2026 *
-
Yield 2027 * -
1 day-2.16%
1 week+6.52%
1 month-1.19%
3 months-9.20%
6 months-24.73%
Current year-25.54%
1 week 18.96
Extreme 18.96
20.7
1 month 18.41
Extreme 18.41
20.7
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
09/07/26 Free

Director

24,532 0.0556%
04/03/26 Tax

Chief Financial Officer

1,744 0.0038%
17/12/25 Fiscal year

Executive/Senior Manager

29,361 0.0639%
Change 5-day change 1-year change 3-year change Capi.($)
-2.16%+6.52%-4.82%-67.14% 88Cr
-0.53%-3.95%+55.23%+152.74% 1,02400Cr
+0.21%-2.68%+55.61%+53.02% 62TCr
-2.51%-3.25%+32.76%+67.76% 44TCr
+0.06%-0.42%+37.53%+30.67% 35TCr
-0.14%-0.24%+34.41%+39.01% 30TCr
-0.69%-0.30%+11.55%+12.93% 26TCr
-7.37%-4.40%-2.54%-43.87% 21TCr
-0.64%+2.43%+30.52%+64.49% 21TCr
-0.82%+0.70%+15.96%+71.01% 16TCr
Average -1.46%-0.42%+26.62%+38.06% 35.75TCr
Weighted average by Cap. -0.99%-1.93%+39.23%+72.92%

Financials

2026 *2027 *
Net sales 75Cr 65Cr 60Cr 55Cr 104.54Cr 7.11TCr 106.16Cr 710.73Cr 278.94Cr 3.54TCr 279.86Cr 273.72Cr 12TCr 78Cr 68Cr 63Cr 58Cr 109.24Cr 7.43TCr 110.93Cr 742.69Cr 291.48Cr 3.7TCr 292.45Cr 286.02Cr 12TCr
Net income 6.4Cr 5.56Cr 5.18Cr 4.75Cr 8.98Cr 610.95Cr 9.12Cr 61Cr 24Cr 304.16Cr 24Cr 24Cr 1.02TCr 8.4Cr 7.3Cr 6.8Cr 6.24Cr 12Cr 801.87Cr 12Cr 80Cr 31Cr 399.2Cr 32Cr 31Cr 1.34TCr
Net Debt 33Cr 28Cr 26Cr 24Cr 46Cr 3.11TCr 46Cr 310.26Cr 121.77Cr 1.55TCr 122.17Cr 119.49Cr 5.18TCr 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 29Cr 190.91Cr 75Cr 951.26Cr 75Cr 74Cr 3.19TCr
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
31/26/31 $19.94 -2.16% 3,67,629
30/26/30 $20.38 -0.97% 3,55,683
29/26/29 $20.58 +2.13% 3,21,673
28/26/28 $20.15 +5.06% 3,90,836
27/26/27 $19.18 +2.46% 2,85,919
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
19.94USD
Average target price
22.00USD
Spread / Average Target
+10.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock